HOLX-RM.ME Stock Analysis
HO
Neutral
Based on Eyestock quantitative analysis, HOLX-RM.ME`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. The company is headquartered in Marlborough, Massachusetts and currently employs 6,944 full-time employees. The firm operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics segment offers a range of diagnostics products, such as ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. Its Breast Health segment offers a portfolio of solutions for breast cancer care, primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment offers a range of products, such as NovaSure Endometrial Ablation System, MyoSure Hysteroscopic Tissue Removal System and Fluent Fluid Management system as well as its Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, and the Fluoroscan Insight FD mini C-arm.